Nina Keldsen

Summary

Affiliation: Herning Hospital
Country: Denmark

Publications

  1. ncbi request reprint Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Nina Keldsen
    Department of Oncology, Herning Hospital, Herning, Denmark
    Gynecol Oncol 88:118-22. 2003
  2. ncbi request reprint [Picture of the month: vena cava superior syndrome]
    Tarec Christoffer El-Galaly
    Herning Sygehus, Røntgenafdelingen, Diagnostisk Center
    Ugeskr Laeger 169:3118. 2007
  3. doi request reprint Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 23:73-80. 2013
  4. doi request reprint Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer
    Troels K Bergmann
    School of Pharmacy, University of Queensland, Brisbane, QLD, AustraliaClinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, DenmarkDepartment of Clinical Genetics, Odense University Hospital, Odense, DenmarkClinical Pharmacology, Department of Medical and Health Sciences, Linkoping University, Linkoping, SwedenScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology, Solna, SwedenDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Herlev Hospital, Herlev, DenmarkDepartment of Oncology, Lund Hospital, Lund, SwedenDepartment of Oncology, Herning Hospital, Herning, DenmarkDepartment of Biochemistry and Pharmacology, Odense University Hospital, Odense, DenmarkClinical Epidemiology, Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany
    Basic Clin Pharmacol Toxicol 110:199-204. 2012
  5. ncbi request reprint Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials
    Parvin Adimi
    Acta Oncol 41:202-3. 2002
  6. ncbi request reprint [Treatment of Danish cancer patients in Hammelburg. A retrospective study of 34 patients]
    Lene W Vestermark
    Odense Universitetshospital, Onkologisk afdeling R
    Ugeskr Laeger 166:1225-8. 2004

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Nina Keldsen
    Department of Oncology, Herning Hospital, Herning, Denmark
    Gynecol Oncol 88:118-22. 2003
    ..The protocol was later amended to include patients with relapse within 12 months...
  2. ncbi request reprint [Picture of the month: vena cava superior syndrome]
    Tarec Christoffer El-Galaly
    Herning Sygehus, Røntgenafdelingen, Diagnostisk Center
    Ugeskr Laeger 169:3118. 2007
  3. doi request reprint Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 23:73-80. 2013
    ..The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab...
  4. doi request reprint Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer
    Troels K Bergmann
    School of Pharmacy, University of Queensland, Brisbane, QLD, AustraliaClinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, DenmarkDepartment of Clinical Genetics, Odense University Hospital, Odense, DenmarkClinical Pharmacology, Department of Medical and Health Sciences, Linkoping University, Linkoping, SwedenScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology, Solna, SwedenDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Herlev Hospital, Herlev, DenmarkDepartment of Oncology, Lund Hospital, Lund, SwedenDepartment of Oncology, Herning Hospital, Herning, DenmarkDepartment of Biochemistry and Pharmacology, Odense University Hospital, Odense, DenmarkClinical Epidemiology, Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany
    Basic Clin Pharmacol Toxicol 110:199-204. 2012
    ..This finding has implications for the understanding of bone marrow suppression and future tailored chemotherapy. ..
  5. ncbi request reprint Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials
    Parvin Adimi
    Acta Oncol 41:202-3. 2002
  6. ncbi request reprint [Treatment of Danish cancer patients in Hammelburg. A retrospective study of 34 patients]
    Lene W Vestermark
    Odense Universitetshospital, Onkologisk afdeling R
    Ugeskr Laeger 166:1225-8. 2004